We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Illumina and UNTHSC Apply New Sequencing Technologies to Forensics

By LabMedica International staff writers
Posted on 11 Oct 2011
Illumina (San Diego, CA, USA) has entered into a collaboration with the University of North Texas Health Science Center (UNTHSC; Fort Worth, TX, USA) focused on applying the firm's next-generation sequencing technologies to forensics. More...


The partners intend to study a range of genetic markers for human identity testing, pharmacogenetics for molecular autopsy, microbial forensics, and other markers and methods that could generate investigative leads in criminal cases or for national security applications. Further terms of the alliance were not disclosed.

Illumina will work with scientists at UNTHSC's Institute of Applied Genetics and the department of forensic and investigative genetics to develop and validate assays for forensic identification.

"Our work with Illumina enables us to design sample preparation, analytical protocols, hardware, and software that expand the capabilities of forensic DNA analysts," Bruce Budowle, executive director of UNT's Institute of Applied Genetics and vice chair of the department of forensic and investigative genetics, said in a statement. "Results of these projects will allow forensic scientists to accelerate implementation of the next wave of forensic DNA analysis tools."

Illumina is a leading developer and manufacturer of life science tools and integrated systems for the analysis of genetic variation and function. The company provides innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA, and protein. The technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare.

Related Links:
Illumina
University of North Texas Health Science Center



New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
Repetitive Pipette
VWR® Stepper Pro
New
Clinical Informatics Platform
CLARION™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.